IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3300 participants.

Also called NCT07875179

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07875179
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07875179. Randomized; no masking; primary purpose treatment. Start 2026-09-28 (anticipated); primary completion 2028-09-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
Acronym
IMPROVE-STEMI
Condition
ST Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
Recombinant Streptokinase
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University (class: other)
Collaborator
China Association for Disaster & Emergency Rescue Medicine (class: not stated)
Collaborator
Henan Singtier Pharmaceutical Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct07875179
Content hash
0effa2a32aac45e1ff64c8b1e13f1813c52ddfea6d7cf828b803d7130c4988fa